Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research

前列腺癌主动监测研究 (PASS) 队列：癌症研究的基础设施支持

• 批准号: 10463567
• 负责人: DANIEL W. LIN
• 金额: $ 127.8万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10463567
• 关键词: Address; Anxiety; Biological; Biological Markers; Biological Specimen Banks; Biology; Biometry; Cancer Patient; Cessation of life; Characteristics; Clinical; Clinical Data; Clinical Management; Cohort Studies; Collection; Communities; DNA; Data; Databases; Decision Making; Diagnosis; Diet; Disease; Disease Progression; Disseminated Malignant Neoplasm; Eligibility Determination; Ensure; Epidemiology; Financial Hardship; Foundations; Funding; Future; Goals; Grant; Health; Individual; Infrastructure; Intervention; Left; Life Style; Malignant Neoplasms; Malignant neoplasm of prostate; Medical; Molecular; Monitor; Morbidity - disease rate; Newly Diagnosed; Outcome; Participant; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Pattern; Physical activity; Plasma; Population; Prognostic Marker; Prospective Studies; Prostate; Protocols documentation; Public Health; Quality of life; Randomized; Recommendation; Recurrence; Regimen; Regrets; Research; Research Personnel; Resources; Sampling; Selection Criteria; Serinus; Serum; Specimen; Standardization; Technical Expertise; Testing; Time; Tissues; Translating; Uncertainty; Urine; active method; adverse outcome; anticancer research; base; cancer biomarkers; cancer care; cancer diagnosis; cancer epidemiology; cohort; comparative; curative treatments; design; economic evaluation; epidemiologic data; follow-up; improved; lifestyle factors; male; men; mortality; overtreatment; personalized approach; personalized management; preference; prospective; prostate cancer progression; prostate cancer risk; response; risk prediction model; risk stratification; side effect; success; surveillance study; tool; tumor behavior; tumor progression

PROJECT SUMMARY/ABSTRACT We propose to support the established Prostate cancer Active Surveillance Study (PASS) cohort, which is a large multi-institutional cohort of men with clinically localized prostate cancer who have elected active surveillance to manage their cancer. With broad eligibility criteria designed to represent the population of men who utilize active surveillance, the cohort has over 2,100 participants with extensive clinical and epidemiological data (demographic, lifestyle, quality of life, long-term outcomes) and longitudinal biospecimens (germline DNA, serum, plasma, urine, and prostate tissue) collected according to a standardized protocol. The cohort was established in 2008 in response to the growing evidence of prostate cancer overtreatment and the need for a prospective study to discover and validate biomarkers of prostate cancer progression, and to identify determinants of cancer progression and patient outcomes. Over the past decade, the cohort has amassed a wealth of data and biospecimens so that it serves as the foundation for addressing critical questions relevant to the optimal personalized management of early stage prostate cancer. The successful funding of this application will support a robust infrastructure for PASS that in turn will ensure the availability of PASS data and specimens to facilitate research addressing determinants of cancer progression, recurrence, and outcomes. A substantial proportion of these research endeavors are encompassed in currently funded federal grants, and the successful completion of the current and future projects relies on the continued success of the PASS enterprise. The impact of this cohort lies in its potential to investigate research questions of paramount importance: to identify better prognostic markers of prostate cancer aggressiveness; to understand the clinical management, progression and outcomes of early stage prostate cancer; to tailor the approach of active surveillance based on individual characteristics and preferences; to characterize associations between clinicopathologic factors, patient lifestyle, and disease biology; to develop new tools to communicate medical information to patients; and to understand decision- making among patients on active surveillance, in particular with regards to quality of life, anxiety, and regret . The successful completion of these transformative research endeavors will address unmet needs in the most commonly diagnosed male cancer and substantially reduce the current public health burden of early stage prostate cancer.

项目摘要/摘要 我们建议支持已建立的前列腺癌主动监测研究（Pass）队列，这是 大型多机构的男性患有临床局部前列腺癌的男性，他们选举了活跃 监测管理癌症。旨在代表男子人口的广泛资格标准 利用主动监视的人，该队列拥有2100多名参与者，具有广泛的临床和 流行病学数据（人口统计学，生活方式，生活质量，长期结局）和纵向生物测量 （种系DNA，血清，血浆，尿液和前列腺组织）根据标准方案收集。这 在2008年建立了队列，以应对日益增长的前列腺癌过度治疗和 需要一项前瞻性研究，以发现和验证前列腺癌进展的生物标志物，并 确定癌症进展和患者结局的决定因素。在过去的十年中，该队列有 积累了大量的数据和生物测量，因此它是解决关键的基础 与早期前列腺癌的最佳个性化管理有关的问题。 该应用程序的成功资金将支持通行证的强大基础架构，从而确保 通过数据和标本的可用性，以促进研究癌症决定因素的研究 进步，复发和结果。这些研究的很大一部分是 涵盖当前资助的联邦赠款，并成功完成当前和未来 项目依靠Pass Enterprise的持续成功。该队列的影响在于它的潜力 调查至关重要的研究问题：确定前列腺的更好的预后标记 癌症侵略性；了解早期的临床管理，进步和结果 前列腺癌；根据个人特征和 偏好；表征临床病理因素，患者生活方式和疾病之间的关联 生物学;开发新工具以向患者传达医疗信息；并了解决策 - 在积极监视的患者中，尤其是在生活质量，焦虑和遗憾方面。 这些变革性研究的成功完成将最大程度地满足未满足的需求 通常诊断出男性癌症，并大大减轻了早期的当前公共卫生负担 前列腺癌。